POST Online Media Lite Edition


Ampio Pharmaceuticals appoints three experienced executives

Christian Fernsby |
Englewood, Co., USA - Ampio Pharmaceuticals, a biopharmaceutical companys, announced the appointments of Howard Levy as chief medical officer and J. Kevin Buchi and Michael Martino to the board of directors.

Article continues below

Howard Levy has over 30 years of experience in the pharmaceutical industry, working with both public and private biotechnology companies on clinical and drug development strategy and execution.

Dr. Levy was most recently Chief Medical Officer of Catalyst Biosciences, Inc.

Prior to that, he was the Senior Global Medical Program Director at CSL Behring; Senior Vice President and Chief Medical Officer at Inspiration Biopharmaceuticals; Chief Medical Officer at Sangart, Inc.; Associate Vice President, Clinical Research, Medical and Regulatory Affairs, at Novo Nordisk; Clinical Research Physician and Medical Director, Acute Care in the U.S. Medical Division of Eli Lilly and Company.

Dr. Levy was also Chief of Critical Care Medicine at the University of New Mexico in Albuquerque for 11 years.

Dr. Levy holds M.B.B.Ch. and Ph.D. degrees from University of the Witwatersrand in Johannesburg, South Africa, and a M.M.M. from Carnegie Mellon University's H. John Heinz III College.

J. Kevin Buchi is the former President and Chief Executive Officer of Cephalon, Inc., having also served as corporate vice president of global branded products at Teva Pharmaceutical Industries Limited after Teva acquired Cephalon in October, 2011.

He also served as President and Chief Executive Officer of TetraLogic Pharmaceuticals.

Mr. Buchi joined Cephalon in 1991 and held various leadership positions during his tenure, including Chief Financial Officer and Chief Operating Officer, before becoming Cephalon's Chief Executive Officer in 2010.

In addition, he currently serves as a Director of Amneal Pharmaceuticals, Inc. and Benitec Biopharma Ltd, as well as Chairman of the Board and Independent Director of Dicerna Pharmaceuticals, Inc.

Mr. Buchi previously served on the boards of several pharmaceutical companies, including EPIRUS Biopharmaceuticals, Inc., Alexza Pharmaceuticals, Inc., and Forward Pharma.

Mr. Buchi holds a B.A. in Chemistry from Cornell University and a Master of Management, Accounting, and Finance from the Northwestern University Kellogg School of Management.

Michael Martino has extensive experience in the life sciences, spanning a 35 year career.

Mr. Martino is currently acting CEO and Director of HemaFlo Therapeutics and serves on the board of Caravan Biologix.

Prior to HemaFlow, he was President and CEO of Ambit Biosciences, a San Diego-based company developing a drug to treat Acute Myeloid Leukemia, from November, 2011, to November, 2014.

Mr. Martino previously served as CEO, President, and a Director of Arzeda, a synthetic biology company, and Sonus Pharmaceuticals, an oncology drug development company.

He was a founding Director at Excision Biotherapeutic.

Mr. Martino's career began with Mallinckrodt, where he held over 20 discreet assignments in planning, business development, marketing, and general management over his 17- ear tenure.